BIOVECTRA and Revolution Biomanufacturing announced a partnership to integrate Revolution’s sequence‑optimization platforms for UTRs and codon usage with BIOVECTRA’s end‑to‑end GMP capabilities from pDNA to sterile drug product. The collaboration promises three‑to‑fivefold increases in protein expression through AI‑driven codon and UTR optimization and aims to give sponsors a single vendor path from sequence design through clinical‑scale LNP and sterile manufacturing.